title: [How I treat ... lentigo maligna by topical imiquimod].
abstract: Lentigo maligna is a special form of in situ cutaneous melanoma that develops on the face of sun worshipers. The topic immunostimulator imiquimod can destroy the neoplasm before it expresses its invasive potential. A strict clinical follow-up of the treated zone must be observed at least 5 years to detect any early sign of recurrence.
authors.affiliation: CHR hutois, Service de Dermatologie, Huy.
authors.forename: R
authors.initials: R
authors.lastname: Bourguignon
authors.forename: P
authors.initials: P
authors.lastname: Paquet
authors.forename: P
authors.initials: P
authors.lastname: Quatresooz
authors.forename: G E
authors.initials: GE
authors.lastname: Piérard
mesh_terms: D000287:Administration, Topical; D000634:Aminoquinolines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000188:drug therapy*; D000077271:Imiquimod; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod